Malondialdehyde-Modified LDL as a Marker of Acute Coronary Syndromes

Open Access
Publisher Website
Google Scholar
Abstract
Ischemic injury of endothelium is associated with prostaglandin synthesis and platelet adhesion and aggregation, which may be associated with the release of aldehydes that substitute the lysine residues in the apolipoprotein B-100 moiety of low-density lipoprotein (LDL) in the absence of lipid peroxidation.1,2 This type of oxidatively modified LDL is referred to as malondialdehyde (MDA)-modified LDL.3 Plasma levels of MDA-modified LDL are increased in patients with acute coronary syndromes, ie, unstable angina or acute myocardial infarction (AMI).3,4 Previously, C-reactive protein5 and cardiac troponins6-9 have been proposed as diagnostic markers of acute coronary syndromes. In this study, we compared the usefulness of MDA-modified LDL as a marker of acute coronary syndromes with that of C-reactive protein and troponin I.